PET imaging of somatostatin receptors using [68GA]DOTA-D-Phe1-Tyr3-octreotide:: First results in patients with meningiomas

被引:0
|
作者
Henze, M
Schuhmacher, J
Hipp, P
Kowalski, J
Becker, DW
Doll, J
Mäcke, HR
Hofmann, M
Debus, J
Haberkorn, U
机构
[1] Univ Heidelberg, Dept Nucl Med, D-69120 Heidelberg, Germany
[2] German Canc Res Ctr, D-6900 Heidelberg, Germany
[3] Univ Basel Hosp, CH-4031 Basel, Switzerland
[4] Hannover Med Sch, D-3000 Hannover, Germany
关键词
somatostatin receptors; DOTATOC; Ga-68; PET; meningioma;
D O I
暂无
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
Imaging of somatostatin receptors (SSTRs) using [In-111]diethylenetriaminepentaacetic-acid-octreotide (DTPAOC) has proven to be helpful in the differentiation of meningiomas, neurinomas or neurofibromas, and metastases as well as in the follow-up of meningiomas, A drawback of the SPECT method is its limited sensitivity in detecting small meningiomas. Because of PET's increased spatial resolution and its ability to absolutely quantify biodistribution, a PET tracer for SSTR imaging would be desirable. Methods: 1,4,7,10-tetraazacyclododecane-N,N ' ,N "N ' ' ' -tetraacetic-acid-D-Phe(1)-Tyr(3)-octreotide (DOTATOC) was labeled using the positron-emitting generator nuclide Ga-68. We acquired dynamic PET images over 120 min after intravenous injection of 175 MBq [Ga-68]DOTATOC in 3 patients suffering from 8 meningiomas (WHO I-o; 7- to 25-mm diameter). Patients' heads had been fixed using individually shaped fiber masks equipped with an external stereotactic localizer system to match PET, CT, and MRI datasets. Results: [68Ga]DOTATOC was rapidly cleared from the blood (half-life alpha, 3.5 min; half-life beta, 63 min). Standardized uptake values (SUVs) of meningiomas increased immediately after injection and reached a plateau 60-120 min after injection (mean SUV, 10.6). No tracer could be found in the surrounding healthy brain tissue. AH meningiomas (even the 3 smallest [7- to 8-mm diameter]) showed high tracer uptake and could be visualized clearly. Tracer boundaries showed a good correspondence with the matched CT and MRI images. PET provided valuable additional information regarding the extent of meningiomas located beneath osseous structures, especially at the base of the skull. Conclusion: According to our initial experiences, [Ga-68]DOTATOC seems to be a very promising new PET tracer for imaging SSTRs even in small meningiomas, offering excellent imaging properties and a very high tumor-to-background ratio.
引用
收藏
页码:1053 / 1056
页数:4
相关论文
共 50 条
  • [21] NMR studies reveal structural differences between the gallium and yttrium complexes of DOTA-D-Phe1-Tyr3-octreotide
    Deshmukh, MV
    Voll, G
    Kühlewein, A
    Mäcke, H
    Schmitt, J
    Kessler, H
    Gemmecker, G
    JOURNAL OF MEDICINAL CHEMISTRY, 2005, 48 (05) : 1506 - 1514
  • [22] 68Ga-DOTA-Tyr3-Octreotide PET for Assessing Response to Somatostatin-Receptor-Mediated Radionuclide Therapy
    Gabriel, Michael
    Oberauer, Andreas
    Dobrozemsky, Georg
    Decristoforo, Clemens
    Putzer, Daniel
    Kendler, Dorota
    Uprimny, Christian
    Kovacs, Peter
    Bale, Reto
    Virgolini, Irene J.
    JOURNAL OF NUCLEAR MEDICINE, 2009, 50 (09) : 1427 - 1434
  • [23] Kinetic analysis of 68Ga-DOTA0-D phe1-tyr3-oc-treotide (DOTATOC) in untreated meningiomas
    Henze, M
    Dimitrakopoulou-Strauss, A
    Schuhmacher, J
    Hipp, P
    Maecke, HR
    Strauss, LG
    Haberkorn, U
    JOURNAL OF NUCLEAR MEDICINE, 2003, 44 (05) : 244P - 244P
  • [24] 68Gallium-DOTA-Tyr(3)-Octreotide (68Ga-DOTA-TOC) PET in Comparison with Somatostatin Receptor Scintigraphy for Diagnosis of Neuro-Endocrine Tumours
    Gabriel, M.
    Decristoforo, C.
    Kendler, D.
    Dobrozemsky, G.
    Bale, R.
    Von Guggenberg, E.
    Kovacs, P.
    Virgolini, I.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2005, 32 : S54 - S54
  • [25] Difficult diagnosis and localization of focal nesidioblastosis: clinical implications of 68Gallium-DOTA-D-Phe1-Tyr3-octreotide PET scanning
    Kim, Jae Ri
    Jang, Jin-Young
    Shin, Yong Chan
    Cho, Young Min
    Kim, Hongbeom
    Kwon, Wooil
    Han, Young Min
    Kim, Sun-Whe
    ANNALS OF SURGICAL TREATMENT AND RESEARCH, 2016, 91 (01) : 51 - 55
  • [26] Biodistribution of a new chelated somatostatin analogue, [In-111-DOTA-D-Phe-1-Tyr-3]-octreotide; Comparison with [In-111-DTPA-D-Phe-1]-octreotide in humans.
    Krenning, EP
    Bakker, WH
    Kwekkeboom, DJ
    Kooi, PPM
    vanderPluijm, ME
    Behe, M
    Macke, H
    JOURNAL OF NUCLEAR MEDICINE, 1997, 38 (05) : 382 - 382
  • [27] SOMATOSTATIN RECEPTORS IN MENINGIOMAS - A SCINTIGRAPHIC STUDY USING IN-111 DTPA-D-PHE-1-OCTREOTIDE
    MAINI, CL
    TOFANI, A
    SCIUTO, R
    CARAPELLA, C
    CIOFFI, R
    CRECCO, M
    NUCLEAR MEDICINE COMMUNICATIONS, 1993, 14 (07) : 550 - 558
  • [28] Receptor PET/CT Imaging of Neuroendocrine Tumours Using the Ga-68 Labelled, High Affinity Somatostatin Analogue DOTA-1-Nal3-octreotide (DOTA-NOC): Clinical Results in 327 Patients
    Baum, R. P.
    Niesen, A.
    Leonhardi, J.
    Wortmann, R.
    Mueller, D.
    Roesch, F.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2005, 32 : S54 - S55
  • [29] Detection of somatostatin receptor-positive tumours using the new 99mTc-tricine-HYNIC-d-Phe1-Tyr3-octreotide: first results in patients and comparison with 111In-DTPA-d-Phe1-octreotide
    M. Bangard
    M. Béhé
    S. Guhlke
    R. Otte
    H. Bender
    H. R. Maecke
    H. J. Biersack
    European Journal of Nuclear Medicine, 2000, 27 : 628 - 637
  • [30] Detection of somatostatin receptor-positive tumours using the new 99mTc-tricine-HYNIC-D-Phe1-Tyr3-octreotide:: first results in patients and comparison with 111In-DTPA-D-Phe1-octreotide
    Decristoforo, C
    Cholewinski, W
    Donnemiller, E
    Riccabona, G
    Moncayo, R
    Mather, SJ
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE, 2000, 27 (10) : 1580 - 1580